|
Diabetes
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Osteopontin (OPN) is an important factor involved in atherogenesis, and hyperglycemia enhances the transcriptional activity of FoxO1 which is closely association with insulin resistance and diabetes.
|
31096186 |
2019 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
FoxO1 inhibits autophagosome-lysosome fusion leading to endothelial autophagic-apoptosis in diabetes.
|
30689742 |
2019 |
|
Diabetes
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Deletion of FOXO1 in chondrocytes rescues the effect of diabetes on mechanical strength in fracture healing.
|
30904630 |
2019 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
FoxO1 is involved in the pathogenesis of β cell dysfunction, but its link to human diabetes GWAS has not been explored.
|
31527256 |
2019 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
To study their role in diabetic muscle wasting, we created mice with muscle-specific triple knockout of FoxO1/3/4 and induced diabetes in these M-FoxO-TKO mice with streptozotocin (STZ).
|
30523026 |
2019 |
|
Diabetes
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
HDAC4 mutations cause diabetes and induce β-cell FoxO1 nuclear exclusion.
|
30968599 |
2019 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
MicroRNA-223 is essential for maintaining functional β-cell mass during diabetes through inhibiting both FOXO1 and SOX6 pathways.
|
31118273 |
2019 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
These findings suggested that FOXO1 is critical to preserve mitochondrial quantity and function in ECs, and FOXO1 may serve as a therapeutic target for microvascular complications of diabetes.
|
29654945 |
2018 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
Conditions present in diabetes, high glucose (HG), and increased advanced glycation end products (AGEs) stimulated FOXO1 association with the RANKL promoter in vitro, and overexpression of FOXO1 increased RANKL promoter activity in luciferase reporter assays.
|
30279162 |
2018 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
Consequently, we confirmed reduced activity of mTOR signaling components and higher expression of atrophy-related markers typified by FoxO1/atrogin-1/MuRF1 and myostatin-Smad2/3 signaling during the course of diabetes.
|
30510624 |
2018 |
|
Diabetes
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
However, the abundance, and activity, of FOXO1 is reduced by half in adipocytes from patients with diabetes.
|
29724916 |
2018 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
These studies indicate that inflammation plays a major role in diabetes-impaired angiogenesis in endochondral bone formation through its effect on microvascular endothelial cells and FOXO1.
|
28285015 |
2017 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
The impact of FOXO-1 to cardiac pathology in diabetes mellitus and diabetes-related metabolic abnormalities.
|
28781146 |
2017 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
Increased Forkhead box protein 1 (FoxO1) acetylation and nuclear retention was followed by progressive FoxO1 loss in β cells that marked the onset of diabetes.
|
28057752 |
2017 |
|
Diabetes
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Altered FoxO1 expression and activity have been associated with glucose intolerance, dyslipidemia and complications of diabetes.
|
28267275 |
2017 |
|
Diabetes
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Moreover, forced expression of forkhead box protein O1 (FoxO1), an antagonist for activated Stat3, specifically in β-cells ameliorated β-cell EMT and β-cell loss and prevented the onset of diabetes in mice undergoing PDL.
|
28775125 |
2017 |
|
Diabetes
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Teucrium polium extract reverses symptoms of streptozotocin-induced diabetes in rats via rebalancing the Pdx1 and FoxO1 expressions.
|
28738518 |
2017 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our results identify CCN3, a novel transcriptional target of FoxO1 in pancreatic β-cells, as a potential target for therapeutic intervention in the treatment of diabetes.
|
23705021 |
2013 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
FOXO1 impairs whereas statin protects endothelial function in diabetes through reciprocal regulation of Kruppel-like factor 2.
|
23002242 |
2013 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
These data indicate that hepatic FoxO1 deregulation impairs the ability of insulin to regulate hepatic metabolism, contributing to the development of hepatic steatosis and abnormal metabolism in diabetes.
|
16997836 |
2006 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
Activation of FOXO1 may be involved in the pathogenesis of sarcopenia, the age-related decline in muscle mass in humans, which leads to obesity and diabetes.
|
15272020 |
2004 |